[{"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nThe first prediction turned out to be right.\nTake the story of Kalydeco.\nShe knew within days that something was different.\nShe still has a damaged CF gene.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was not based on a press release.", "answer": 1}, {"article": "Ma exposed the mice to either the plant-based or the marine-based omega-3s, beginning in utero.\n\"This study is the first to compare the cancer-fighting potency of plant- versus marine-derived omega-3s on breast tumour development,\" said the professor in the Department of Human Health and Nutritional Sciences.\n\"Seeing the significant benefits omega-3s can have in combatting a highly aggressive form of breast cancer means omega-3s will likely be beneficial for other types of cancer.\"\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nThere are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release gives premature medical advice to \u201cchoose omega-3s from fish over flax for cancer prevention\u201d and \u201cconsume two to three servings of fish a week,\u201d and suggests without evidence that \u201comega-3s will likely be beneficial for other types of cancer.\u201d It veers even further astray by conveying a researcher\u2019s view that \u201csupplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects.\u201d", "answer": 0}, {"article": "TUESDAY, June 14, 2011 (HealthDay News) -- Not only do cooler heads prevail, they might also sleep better, according to researchers who say they have developed a cooling cap that, when worn during sleeptime, may help treat insomnia.\n\"It does reduce brain metabolism in the frontal lobes, and it improves sleep.\"\nThe U.S. National Heart, Lung, and Blood Institute has more on insomnia.\n\"It's in the brain where the chemical changes are occurring that lead to sleep,\" he said.\nBuysee said there shouldn't be any safety issues.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes one of the researchers, and we couldn\u2019t find any evidence that it relied too much on this press release.", "answer": 1}, {"article": "Because the prostate is small and tiny shifts in position can make accurately targeting tumors difficult, OU Physicians has software and a real-time machine that allow doctors to place the seeds exactly where they are needed.\n\"At present time, it seems like they are doing very well,\u201d he said.\nThe 50 to 150 pellets become inert metal after losing their radioactivity.\n\"More and more patients are opting for brachytherapy.\n\"Now it's becoming more common and almost standard,\u201d Kelly said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story was based largely on a news release. ", "answer": 2}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nThere are currently no treatments for Prader-Willi syndrome, the most common genetic cause of life-threatening obesity.\n\u201cWe\u2019re delighted with the results,\u201d Hughes said in an interview.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting that we can be sure the story isn\u2019t based entirely on a news release.", "answer": 1}, {"article": "* Researchers involved in this study are affiliated to the following:\n\nSchool of Medicine, University of East Anglia, Norwich, UK \n\nNorfolk and Norwich University Hospital, Norwich, UK \n\nBristol Medical School, University of Bristol, Bristol, UK \n\nDepartment of Rheumatology, University Hospitals Bristol, Bristol, UK \n\nMedical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK \n\nCollege of Medical and Dental Sciences, University of Birmingham, UK \n\nCentre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital, Birmingham, UK \n\nLeicester Medical School, Centre for Medicine, University of Leicester, UK \n\nNational Institute of Health Research Manchester Musculoskeletal BRU, Central Manchester University Hospitals NHS Foundation Trust & \n\nArthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, UK \n\nDepartment of Health Sciences, University of York, York, UK \n\nCentre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK \n\nMellanby Centre for Bone Research, Centre for Integrated Research into Musculoskeletal Ageing, University of Sheffield, Sheffield, UK \n\nAustralian Catholic University, Melbourne, VIC, Australia\n\u2022 Shepstone et al (2017).\n\"We welcome this community based screening programme and any other research that reduces the likelihood of fractures.\"\nMortality at one-year post-fracture is approximately 20 per cent.\"\n\"A hip fracture can be devastating with a loss of independence and less than one third of patients make a full recovery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language was identified.", "answer": 1}, {"article": "In a 2014 CDC report, the U.S. infant mortality rate (6.1 per 1,000 births) put it in 26th place among a selection of developed countries.\n\u201cI would personally recommend that any woman with a favorable cervix at 39 weeks be encouraged to get induced.\u201d\n\nOf course, Lockwood said, women should be heard.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\nAlso, the drug can cause the placenta to detach from the uterine wall too early, and it can cause the uterine wall to tear.\n\u201cObstetricians are in front of her, hacking through the forest.\u201d\n\nEsther Hausman, a certified nurse midwife in Concord, Mass., argues for restraint.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story published on June 27, 2016 refers to a session at a conference that occurred in May. It is not clear whether the reporter attended the meeting and spoke to the participants or merely relied on second-hand reports of the session. However, the story includes quotes from what appear to be interviews with several sources.", "answer": 1}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\n\u201cIt is important to stress, however, that this treatment is only suitable for patients with relapsing remitting multiple sclerosis disease who have had two or more significant relapses in the past 12 months, failed to respond to standard drug treatment and who have had the illness for at least 10 years.\u201d\n\nOne patient who has undergone the treatment, known as autologous haematopoietic stem cell transplant (HSCT), told the BBC\u2019s Panorama programme that he had made incredible progress.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find any news release that could have spawned this story. However, its use of almost identical sources and direct quotes to those of a BBC News story that was posted earlier on the same day leads us to question the nature of the material used by the newspaper. The BBC claimed that it had been given \u201cexclusive access\u201d to the patients in this clinical trial, but that does not explain\u00a0the details\u00a0in The Guardian. Given the troubling overlap between these stories, we\u2019re reluctant to award a Satisfactory since the story does seem at the very least to have borrowed text either from the BBC or an unknown source news release. We\u2019ll rate this Not Applicable, which means we\u2019re neither crediting nor penalizing the story.", "answer": 2}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\nNearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes comments attributed to a direct email from one of the study authors, so\u00a0we can confirm our overall impression that this story wasn\u2019t based\u00a0on a\u00a0press release.", "answer": 1}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational, unjustified language.\nIt does, however, overstate the findings of the research. The first sentence reads:\n\u201cDieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\u201d\nThis is a definitive statement and at no point in the rest of the release does it state\u00a0that additional research is needed to confirm the findings.", "answer": 1}, {"article": "The original form of vancomycin is an ideal starting place for developing better antibiotics.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "When saying that research has given a drug \u201cnew superpowers,\u201d one expects to find robust and overwhelming data that demonstrates the efficacy of the relevant drug in a clinical setting. That is not the case here. And, frankly, it is difficult to think of a context in which a drug could be accurately described as \u201cmagical.\u201d The language is over the top, particularly for a modified drug \u2014 even a promising one \u2014 that is this far removed from clinical use.", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It is unclear where the author obtained the information. The reuslts have not been presented as yet and the authors were not quoted. It appears that the source was the drug company; no information was given from experts in the field to place this new agent in context. Nonetheless, because we can\u2019t be sure the story relied solely or largely on a news release, we rate it N/A. ", "answer": 2}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n\u201cI would say 70 percent of the patients who come into my office have fungal infections on their toenails.\u201d\n\nThere may be hope.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is not based on a news release. We are going to give this one the benefit of the doubt but wonder where some of the information about the success rate with the Pinpointe FootLaser comes from. The only source we could locate was the company\u2019s press release noting approval of the device by the FDA.", "answer": 1}, {"article": "If you'd like more information about the ONCOblot\u00ae Test, please visit http://www.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\nDallas, Texas -February 4, 2016 - MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot\u00ae Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot\u00ae test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\n\"Although asbestos-induced mesothelioma is a very specific example of early detection, we are currently pursuing larger-scale clinical trials to investigate the utility of the ENOX2 protein marker to predict the onset of cancers of other tissues of origin as well.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are only nine sentences in this release, yet there is room to boast of \u201cexciting results,\u201d \u201cexciting sign of progress\u201d and an \u201cexciting new chapter\u201d that the company is \u201celated to share.\u201d While the study results may well be exciting to some researchers who are planning clinical trials of early treatments for rare mesothelioma cancers, there is nothing in this study that is truly \u201cexciting\u201d to people worried about their personal risk of developing mesothelioma. The release dangles false hope in front of people exposed to asbestos by pushing the popular myth that \u201cearly detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths\u201d.\nAs this online primer summarizes, the triple stumbling blocks of lead time bias, length bias and overdiagnosis stand between this study and any real understanding of whether the news may ever be exciting to people worried about the consequences of exposure to asbestos.", "answer": 0}, {"article": "That\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nLung cancer kills more people in the U.S. than any other cancer \u2014 over 150,000 each year.\nThe new study provides further evidence of that.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear the story didn\u2019t simply rely on a news release.", "answer": 1}, {"article": "Sleep-specific quality of life was examined with the Functional Outcomes of Sleep Questionnaire (FOSQ), which assesses the effect of sleep disorders and excessive daytime sleepiness on activities of daily living such as productivity and intimacy.\nScores before and after up to one year of PAP therapy were compared.\nParticipants had a mean age of 56 years, and about 54 percent were men.\n\"This information will guide clinicians in terms of expected quality of life outcomes with sleep apnea treatment.\"\n\"We noted consistent improvement in global and sleep-specific quality-of-life measures after PAP therapy.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable or sensational language here.", "answer": 1}, {"article": "The pill is his blood pressure medication.\n\"When you get to be my age, you're going to be very grateful that you controlled your blood pressure and exercised,\" he says.\n\"With every pulse of your heart, you are pushing blood into these very small blood vessels in the brain,\" he says.\nIt occurs when something blocks or reduces the flow of blood to brain cells.\n\"We can do that with exercise, with lifestyle, with healthy eating and also with medications.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The Alzheimer\u2019s Association website is promoting its upcoming July annual meeting, but there was no news release specifically addressing the content of this story.", "answer": 1}, {"article": "However, based on some prior studies, independent experts say denosumab appears more effective at preventing spine fractures than three older pills \u2014 Fosamax, Actonel and Boniva \u2014 and calcitonin nasal sprays, which all use various pathways to slow down cells called osteoclasts that break down bone.\nThe biotech company designed the studies, handled data collection and analysis, and helped write the journal reports.\nSpine bone density loss was far smaller for those given the drug.\nThe two studies were released Tuesday by the New England Journal of Medicine.\nThe effectiveness of denosumab and existing drugs appears to plateau after two or three years, she added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This piece included several independent sources and therefore, does not rely on the news release.\u00a0 ", "answer": 1}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\n\"If you can reduce the new skin cancer rates for these patients, it would be an enormous benefit,\" she told CBS News.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\n\"I am absolutely willing to try it and hope for the best,\" she said.\nShe said she's had \"quite a few on the top of my head, a few on the back of my head, one behind each ear,\" even though she tries to stay out of the sun.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since two outside experts are quoted, we can be sure the story didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story includes quotes from a variety of experts. It seems clear it did not rely on a news release.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The report does not appear to rely on a press release.", "answer": 1}, {"article": "However, one expert was not sold on this new drug.\n\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\nAlso, it does not have the same problems as the previous weight-loss drugs, Fen-Phen (Phentermine), Acomplia (rimonabant) or Meridia (sibutramine), which had been associated with heart problems, he said.\n\"What's most impressive about this two-year clinical trial is how unimpressive it is,\" said Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We rule this satisfactory because it\u2019s clear that the story goes beyond the news release. \nBut the top of the story does feature some marketing-like language, including these two quotes: \"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith\u2026 \"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what\u2019s going to be available for helping patients lose weight,\" he added.", "answer": 1}, {"article": "Researchers here quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente, where 1,208,710 women have undergone triennial cervical cotesting since 2003.\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nHPV testing is more sensitive than the Pap test for detecting precancer.\nKaiser Permanente has now screened over a million women by cotesting.\nThe Pap test can also find noncancerous conditions, such as infections and inflammation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no unjustifiable language.", "answer": 1}, {"article": "Good clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This article does not appear to rely on a press release.", "answer": 1}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nAgave, artichokes, garlic, onions and chicory are rich, natural sources of fructans -- nondigestible carbohydrates consisting of molecules of fructose linked together into chains, according to background information in a news release from the American Chemical Society.\nCompared to other mice, those fed agave fructans absorbed more calcium from food, excreted less calcium in their feces, and had a 50 percent increase in levels of a protein associated with the build-up of new bone tissue.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story admits that it is based on \"background information in a news release from the American Chemical Society.\"", "answer": 0}, {"article": "The longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nThe relationship held even after the researchers adjusted for potential confounders that could affect the risk of skin cancer, such as use of other medications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story acknowledges lifting a quote from this press release, but there\u2019s no evidence that the story used any other content from the release. We can\u2019t be sure about this one, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear some original reporting was done and that the story did not rely excessively on a JAMA news release. That release did have some useful information (e.g. roughly how many pregnant women take SSRIs, the\u00a0mortality rate of PPHN, confounding factors, etc.).", "answer": 1}, {"article": "Gaziano and colleagues created a computer simulation to see if giving statins to more people would be worth the risk of side-effects and the extra cost.\nPatients and doctors alike complained that the new guidelines were confusing.\nThey can damage muscle in 5 to 15 percent of patients.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely excessively on a news release.", "answer": 1}, {"article": "This, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nWorse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nHowever, this has been shown to be false.\nIt\u2019s like Bizarro world, where everything is backward.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough context here that we can be sure the story does not rely on a news release.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to rely on a news release.", "answer": 1}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nI\u2019m not suggesting that we start serving coffee to little kids.\nWhole interventions would be built up around it.\nI\u2019m also not suggesting that people start drinking coffee by the gallon.\nToo much of anything can be bad.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s difficult to envision a news release that could account for this story.", "answer": 1}, {"article": "Budd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\nIt works like a lock on a canal, he said.\nThe water height can be adjusted to the patient\u2019s abilities.\nSome pools may loan them out, too.\n\u201cTaking some of that pressure off the knee helps them tolerate that knee injury longer,\u201d said Johnson.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "Now a new study from researchers at Harvard reports that Americans who eat two or more servings of brown rice a week reduce their risk of developing Type 2 diabetes by about 10 percent compared to people who eat it less than once a month.\n\u201cThe bottom line is we showed evidence that increased consumption of white rice \u2013 even at this low level of intake \u2014 is still associated with increased risk,\u201d said Dr. Sun, who was at the Harvard School of Public Health when the study was done.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nCorrection: An earlier version of this story misidentified the amount of cooked rice in a serving.\nA serving is half a cup of cooked rice.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not\u00a0 applicable because we can\u2019t be sure of the extent to which the story was influenced by a Harvard news release.\u00a0 We are sure that the story didn\u2019t quote any independent sources \u2013 just\u00a0 the study author.\u00a0", "answer": 2}, {"article": "At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\nOtherwise, lots of people would have early heart disease but no obvious risk factors.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\n\u201cOur main job is to find the gene,\u201d Dr. Biesecker said.\nMr. Del Sontro drank only water and took small portions.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story wasn\u2019t based on a press release.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 We do know that it only quoted one source \u2013 a study author.\u00a0 ", "answer": 2}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe results supported the use of high-dose definitive radiation therapy, via proton beam therapy, for selected patients with unresected spine and sacral chordomas.\"\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nOnly about 300 Americans are diagnosed with this cancer each year.\nSaid Tracy, \"We were told that I should prepare myself for the loss of functionality below the waist \u2013 including bowel, bladder and sexual functions.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational language. It makes no particular claims about the effectiveness of the relevant treatment option but notes only that it poses fewer risks than other radiation treatment options.", "answer": 1}, {"article": "April 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\n\"If thyme tincture is proven to be as clinically effective as our findings suggest, it may be a natural alternative to current treatments,\" researcher Margarita Gomez-Escalada, PhD, says in a news release.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The only quotes from the researchers themselves came from a news release, but there were four independent experts quoted.\u00a0 So the story didn\u2019t technically rely solely or largely on a news release \u2013 which is our criterion.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nA 2005 research review concluded that people who drank the most coffee were one-third less likely to develop diabetes than those who drank the least, Dr. Rachel Huxley of The University of Sydney, Australia, and colleagues note.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied solely or largely on a news release.\u00a0", "answer": 1}, {"article": "The findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nAbout 1 in 5 patients required additional medication to control their pain.\n: Link will be live at the embargo time http://jamanetwork.\nStudy Limitations: The results apply only to pain after two hours.\nDespite the epidemic, opioid analgesics remain a first-line treatment for moderate to severe acute pain in the emergency department.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "(Reuters Health) - Women who take part in exercise, diet programs or a combination of the two during pregnancy can prevent excessive weight gain, according to a fresh review of past research.\nThe women who took part in diet, exercise and combination programs were also less likely to develop high blood pressure during pregnancy, compared to those in the standard care group.\nThe women were randomly assigned to a diet, exercise, a combination of the two or standard care.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\nThen, during the next pregnancy the woman is already heavier and that may increase the risk of complications.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cited at least one independent source and drew on material from the Institute of Medicine.", "answer": 1}, {"article": "Editor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\nFor more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\n\"That suggests vitamin D can augment the effect of weight loss on inflammation.\"\nVitamin D is a steroid hormone that has multiple functions beyond its widely recognized role in regulating calcium levels and bone metabolism.\n\"Weight loss reduces inflammation, and thus represents another mechanism for reducing cancer risk,\" Duggan said.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "None detected.", "answer": 1}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\nEach patient would receive just one treatment directed into the brain, followed weeks later by a series of intravenous treatments with Avastin.\nBut how long the effect will last remains to be seen.\nIt consists mainly of cells that line the walls of capillaries in the brain and are so tightly packed that many molecules in the bloodstream cannot slip out between cells to reach the brain tissue itself.\nWhat\u2019s exciting about our results is that we\u2019ve proven there is a local effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that the story relied on a news release. ", "answer": 1}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\nThey implanted electrodes into the area and connected them to a pulse generator under the skin.\nThe patients, all women, were aged between 24 and 57 and had had anorexia for between four and 37 years.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\nScientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that story relied solely or largely on a news release.", "answer": 1}, {"article": "Study author Dr. Kang Zhang, the chief of ophthalmic genetics at UC San Diego's Shiley Eye Institute, told CBS News, \"Unlike [the] current way of cataract surgery, which destroys over half of lens stem cells and requires implantation of a plastic intranet ocular lens, we devised a new surgery to make a very small opening at the side of a cataractous lens bag, remove [the] cataract inside, allow the opening to heal, and promote dormant lens stem cells to regrow an entirely new lens with vision.\"\nIf you think about the implications in the long run, lens implants may not be necessary,\" he said.\n\"I would anticipate that it may be available after several independent studies with a large number of patients,\" he said.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\nZhang said their results need to be validated in a large number of patients \"and with a longer follow-up period.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Given the multitude of independent sources, this story doesn\u2019t appear to rely on a news release.", "answer": 1}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nThere was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\nThe reduced risk was largely due to fewer cases of gastrointestinal cancers, including colon cancer, rectal cancer and esophageal cancer.\nEric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society, said the new study \"confirms the now well-established link between regular aspirin use and lower risk of developing certain cancers of the gastrointestinal tract -- cancers of the colon, rectum and esophagus.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story rates a Satisfactory because it clearly went beyond both the American Association of Cancer Research news release\u00a0and this news release from the Harvard School of Public Health. However, it\u2019s equally clear that these news releases and the conference presentation were the primary basis for the story. As noted above under the Novelty criterion, we think a story that provided \u00a0a broader, more inclusive view of the evidence would been more useful to readers.", "answer": 1}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\nIn that situation, the procedure is called late angioplasty.\n\u201cWhy not open it late?\nThe study was also published online yesterday by The New England Journal of Medicine and will appear in the Dec. 7 issue.\nBy late afternoon, the rally had wiped out all the morning losses.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely exclusively on a press release", "answer": 1}, {"article": "For more information, visit http://www.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nOTTAWA, ON - August 21, 2017 - Researchers at the Children's Hospital of Eastern Ontario (CHEO) looked at the incidence of and risk factors associated with sedation-related adverse events in pediatric emergency departments as part of a multi-centre observational study published today in JAMA Pediatrics.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language.\u00a0 We think the release may have strayed into unjustifiable territory by suggesting the study findings may be \u201cpractice-changing.\u201d That remains to be seen but we\u2019ll give the release the benefit of the doubt on this claim.", "answer": 1}, {"article": "One study published in Psychological Science trained 16 college-aged adults and 16 older adults (around age 71) with Gabor patch exercises for 1.5 hours per day for seven days.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nScientists don\u2019t know exactly how perceptual learning relieves presbyopia, but they have some clues based on how our brain processes visual information.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the Glassesoff app team recently issued a media \u201ckit\u201d and news release, the story\u2019s author has clearly been using the product for months. There is much original reporting and we don\u2019t see any evidence that the story relied excessively on a news release.", "answer": 1}, {"article": "The volunteers drank a 10-ounce glass of cherry-flavored liquid that contained two and a half ounces of fructose or glucose.\nThere was no difference in leptin or ghrelin levels between fructose and glucose drinkers.\nThe volunteers were then presented with images of high-calorie foods and asked whether they would like to have the food now, or a monetary award a month later instead.\n\u201cInsulin is released when we consume glucose,\u201d she said.\n\u201cThe pancreas secretes insulin, and insulin drives glucose into cells so that it can be used for energy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not draw from any news release that we could find. It appears to include original reporting from an interview with one of the study authors.", "answer": 1}, {"article": "This is the experience many women have.\n\"He was screaming and then I remember that when I started to talk to him he stopped.\nShe was alert, her head was up and the drape lowered so she could watch the delivery of her son, Connor.\nHer only memory of meeting her newborn son for the first time was from some pictures her husband took.\nNow some hospitals are offering small but significant changes to the procedure to make it seem more like a birth than major surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to be based on any press releases. The quotes and sources used show signs of original reporting.", "answer": 1}, {"article": "\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nAccording to those who use this anterior technique, the benefits are substantial.\nUnger performed both surgeries.\nMany patients aren\u2019t aware of the option.\nI was home in three days, and a week later, [I] walked one or two blocks without pain or a cane.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a press release.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This appears to be an enterprise story, and does not rely on a news release.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The feature was not based on a release as far as we can tell from the university\u2019s news release site.", "answer": 1}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, AUGUST 16, 2016\n\nMedia Advisory: To contact Paul D. Miller, M.D., call 303-925-4514 or email millerccbr@aol.com.\nThe trial was conducted at 28 sites in 10 countries.\n: This study was funded by Radius Health.\nOverall, there were no differences in serious adverse events between the treatment groups.\nBone mineral density (BMD) increases were greater with abaloparatide than placebo.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There is no unjustifiable language in the release.", "answer": 1}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\n\"I've always compared it to being like a toddler learning how to, you know, walk, write, eat.\"\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although the story focused on just one patient at one institution, there is no way to know if the story relied on a press release as the sole source of information. ", "answer": 2}, {"article": "The findings are published on line in the journal EBioMedicine, published by The Lancet.\nResearchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Highlighting \u201cnew hope\u201d in the headline, and claiming \u201cthe results so far are very promising,\u201d are unjustified given this is a small, preliminary study showing changes in surrogate markers only two weeks after treatment in 28 subjects.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication that this story relied on a news release.\u00a0 However, the researcher\u2019s institution did produce a news release in 2014 that in some respects mirrors the Fox News story, relying on the anecdotes of one patient and comments from the inventor.", "answer": 1}, {"article": "The results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nThe condition tends to develop with age and can lead to chest pain, shortness of breath, fatigue and heart failure.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\nAfterward, patients could walk significantly further in six-minute walking tests used to assess their functional capacity.\nOn average, they added almost 42 meters (138 feet) to their performance before surgery.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\nThe potential of irisin as a meaningful drug target in PCOS is very promising,\" said Dr Bacopoulou.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses language responsibly. It doesn\u2019t say that this will be a valuable diagnostic tool, but that it is a promising first step. As a result, we give it a satisfactory rating. However, the release ends by referring to irisin\u2019s potential as a drug target for future PCOS treatments. This is in a quote from a researcher, and is given in the context of \u201cfuture directions\u201d for the work, but it walks very close to the edge of \u201cunjustifiable language\u201d \u2014 primarily because, to the best of our knowledge, there is no research to support such a statement.", "answer": 1}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\nThis is an important part of breast health,\" she said.\nNot all women with breast cancer experience the same warning signs of the disease.\nIts effectiveness depends on the size of a breast tumor and the density of breast tissue.\n\u2022 Mammogram: An X-ray of the breast used to examine breast changes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story appears to rely entirely on the news release.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cBy also binding with the magnetically tagged peptide, the biomarker is enhanced, generating enough signal for MRI detection of small, high-risk cancer and micrometastases.\u201d\n\nThe researchers tested the approach in mice into which they had introduced breast cancer cells.\n\u201cThe technique used by researchers in this study enables very early detection of metastatic spread, which would allow adaptation of treatment more quickly and hopefully lead to better outcomes in the future.\u201d\n\nThe study, published online in the Aug. 12, 2015, issue of Nature Communications, was led by Zheng-Rong Lu, Ph.D., CWRU M. Frank Rudy and Margaret Domiter Rudy Professor of biomedical engineering and an expert in molecular imaging for cancer and other diseases.\nThese are two things that potentially can make a big impact on clinical practice and also management of cancer.\u201d\n\nOne-third of patients diagnosed with breast cancer eventually develop metastases in distant organs, with an increased risk of death.\n\u201cThe recurrence rates of some forms of breast cancer and the consequence of metastatic cancer make these efforts urgent and important,\u201d said Lu, adding that his research team also hopes to advance the approach for prostate cancer detection.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We\u2019ll give the story the benefit of the doubt here. The headline and lede paragraphs don\u2019t make clear that this is not about standard MRI, or that the work was done in mice. However, we\u2019ve already docked points for those infractions, and we think the language was otherwise responsible.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not rely on any press release.[SJA: agree]", "answer": 1}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\nProduced by Abbott, the CardioMEMS\u00d4 HF System is approved in the United States by the Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The leading quote includes terms such as \u201cepidemic\u201d and \u201cbig game-changer.\u201d First of all, heart failure is not an infectious disease, and only one person has undergone this therapy at the Cardiac Centre.\nThe headline and leading sentence also talks about the device being a \u201cfirst\u201d in Canada without any mention of previous implantation procedures in other countries.\nThese word choices could be misleading and raise red flags in our eyes. Therefore, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "The research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nOf the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control.\nThey returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\nAbout the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not rely on sensationalist language.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s no evidence that the story relied solely on a news release.", "answer": 1}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\n\"And does not involve any radiation or breast compression,\" Schnabel said.\n\"It's just very difficult to be able to pick out the boundaries of that mass.\"\nShe feels her life is back in her own hands.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story has some independent reporting and information does not appear to be taken from a press release.", "answer": 1}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There\u2019s enough original reporting here that we can be sure the story didn\u2019t rely excessively on a news release.", "answer": 1}, {"article": "Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.\n\u201cThe results of Strive represent a real transition for migraine patients from poorly understood, re-purposed treatments, to a specific migraine-designed therapy.\u201d\n\nSimon Evans, chief executive of the charity Migraine Action, said: \u201cMigraine is too often trivialised as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\nAmgen and Novartis, the codevelopers of erenumab, funded the trial, while Amgen also supplied the drug and conducted the data analyses.\nThe condition is linked to depression and sick days caused by migraine are estimated to cost the UK economy more than \u00a32bn per year.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes the principal investigator, Peter Goadsby, but doesn\u2019t note the source of those quotes: A press release by King\u2019s College London, where Goadsby is a professor. So when The Guardian reports that Goadsby \u201csaid\u201d such and such, it implies that he said it directly to someone at\u00a0The Guardian. \u00a0But he did not. \u00a0In fact, we don\u2019t even know if Goadsby \u201csaid\u201d those things or wrote them, in a note to the PR people. \u00a0It\u2019s not a best practice to grab quotes from a PR news release while failing to attribute the source.", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story does not rely solely on a news release.", "answer": 1}, {"article": "(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Everything in the story appears to be based on a Merck announcement.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely or largely on a press release.", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nThe juice is a beautiful wine-red color and tastes delicious.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release. Then again, no sources are cited except a California company, so it\u2019s not clear what sources were relied on. ", "answer": 2}, {"article": "Funding: National Cancer Institute grants P50 CA097248 and P30 CA046592, and the Sinabaldo and Diane Tozzi Research Fund\n\"In trying to match the biology of the tumor to the treatment, all of the patients get better outcomes,\" says study author Gregory T. Wolf, M.D., professor and chair emeritus of otolaryngology - head and neck surgery at Michigan Medicine.\nFor patients who must go on to receive surgery, by selecting them up front, we can spare them the complications that may occur when the voice box is removed following multiple cycles of chemotherapy with radiation,\" adds study author Francis Worden, M.D., professor of hematology/oncology.\nFor the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative treatment with chemotherapy and radiation to try to avoid surgery.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We give this a satisfactory rating, but want to make two notes \u2014 one on something we particularly like to see, one on something that we don\u2019t. First, kudos to the headline on the news release. It clearly conveys the relevance of the finding without overselling it. The headline doesn\u2019t tell us that the technique picks the best course of treatment; instead, the headline tells us that the new technique helps patients and doctors make a decision about what course of action is best. That\u2019s good to see. Lower down, the story refers to a survival rate as \u201cunheard of.\u201d What does that mean? People say and hear all kinds of things. Are they referring to clinical trial results? Longitudinal study findings? Hearsay? When possible, we discourage the use of this sort of vague language; it offers readers little insight, and does more to confuse a subject than to clarify it. The language in this instance was not sufficiently hyperbolic to warrant a \u201cnot satisfactory\u201d rating, but it\u2019s close.", "answer": 1}, {"article": "However this does not help them to overcome their fear in the long term.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nProfessor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is cautious in its use of language, and is very careful to acknowledge the limitations of CBT in addressing dental phobia. For example, the first sentence of the release states that CBT \u201ccould help many people with dental phobia.\u201d It does not say that CBT will help or that it could help all people with dental phobia.", "answer": 1}, {"article": "Soy may keep breast cancer from coming back\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\nMost of the women in the study had never been smokers, and there\u2019s a lot of evidence to suggest that lung cancer is a different disease in smokers versus non-smokers.\nThere are many never-smokers with lung cancer,\u201d she said.\nThere might be an infectious disease that causes some cases of lung cancer \u2014like the virus that causes cervical cancer, or the bacteria that causes stomach cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not seem to have relied inappropriately on this press release. Plus there was an independent expert comment.", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nThey also did not find any significant differences in safety between the two drugs.\nNone of the study investigators, children, or caregivers knew which study drug each child was receiving.\nThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\nThe Division of Pediatric Pulmonology and Allergy/Immunology at UH Rainbow is currently recruiting for a number of asthma-related clinical trials.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release from University Hospitals Case Medical Center does not use unjustifiable, sensational language.", "answer": 1}, {"article": "The bar was developed over the past 10 years by a team of scientists led by Drs.\nThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nWhile poor diets contain much that is not healthy (e.g., too much salt, sugar), they also are missing or deficient in a number of important components (e.g., vitamins/minerals, omega-3 fatty acids, fiber) necessary for healthy metabolism.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release makes unjustified claims of \u201cbroad health improvement\u201d that aren\u2019t backed up by evidence \u00a0The very idea that the bar may be effective for\u00a0individuals who make no other changes in their diet or physical activity levels is highly questionable. The release crosses over into salesmanship in several instances such as this one: \u201cThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\u201d", "answer": 0}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\nThe results of the study were published online March 16 in the New England Journal of Medicine to coincide with a planned presentation of the findings at the American College of Cardiology's annual meeting in San Diego.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n\"This is an unexpected finding, and we want to confirm this in other studies,\" Jolly said.\nFor the study, Jolly and colleagues randomly assigned 10,732 patients undergoing an angioplasty after a heart attack to have clots manually removed or to not have them removed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While there is a press release on this study produced by the conference, the expert interviews are evidence that the story did not rely on them excessively. We\u2019d note that there is some information in the press release that would have made the story better.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the source of the information.\u00a0 No independent source is quoted.\u00a0 There are only brief references to what analysts say.\u00a0 ", "answer": 2}, {"article": "The drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nThere are a couple of reasons for severe hot flashes after breast cancer.\nBut a new study suggests an existing medication may help.\nBoth doses appeared to reduce hot flashes better than the placebo.\nHowever, he cautioned that its long-term effects aren't known.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article included original comments not found in the news release.", "answer": 1}, {"article": "The longer use also makes the IUD and implant more convenient for women, since maintenance is reduced.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nMORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to draw exclusively from this university press release. No independent sources are quoted, and there are substantial similarities between text in the story and the news release.\nHere is a side-by-side comparison:\nNews release: \u201cStudy participants were 18 to 45 years old, and their contraceptives had to be within six months of expiring when they enrolled. The women were informed of a possible risk of pregnancy if the devices were used beyond the time periods approved by the FDA.\u201d\nStory: \u201cAll the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study. The women were informed of the pregnancy risk associated with using their device longer than recommended\u2026\u201d\nConducting just one interview would have removed any doubt as to whether the story relied excessively on the news release.", "answer": 0}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nEach participant had an ultrasound to see if there were signs that a stroke might occur.\nBut those at highest risk may need a surgical procedure called an endarterectomy, which clears the carotid arteries of plaque.\n\"This test could be a good tool to identify the right patients for surgery,\" Topakian said.\nIn addition, over the two years of the study, 10 people had TIAs.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not appear to rely on a news release.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nThese associations persisted even after adjusting for known colorectal cancer risk factors.\nProtective associations were seen in all subgroups examined.\n\"This calibration approach enabled us to systematically explore risk over the broad range of vitamin D levels seen internationally.\"\nArticle: Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no instances of unjustified language.", "answer": 1}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nNone of the patients was deemed eligible for standard surgical interventions.\nTypically, patients were able to return home the following day.\nThe team concluded that cryoablation appears to be both safe and effective, at least in the short-term.\nRather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There isn\u2019t any evidence that the story relied solely or largely on a news release.", "answer": 1}, {"article": "The findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nNor is it clear why the results differed for men and women.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nThis was an observational study and therefore can\u2019t establish cause and effect.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story discloses that its only quote comes from a news release.", "answer": 0}, {"article": "\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe company\u2019s stock plummeted on that news this past June.\nThe idea is to create resistance to an allergen without ever having to expose the patient to that substance.\nAnother reason for the hesitancy: liability concerns.\nBut hope may be on the way.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article was certainly not based on a single news release.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nIn the May issue of the Archives of General Psychiatry, George and his colleagues report the results of their 190-patient study, the most rigorous investigation of TMS for depression so far.\nBut George and his team say they\u2019ve solved that problem by developing a dummy device that clicks in a similar way to the real thing and causes a person\u2019s eye muscles to twitch, just like real a TMS device.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story doesn\u2019t appear to have lifted any copy directly from an NIH news release about the study. Since it included only one expert source who was\u00a0also\u00a0the lead investigator on the study, however,\u00a0we can\u2019t say for sure how much the story relied on the release. We\u2019ll call it not applicable.", "answer": 2}, {"article": "Article reference: R.M.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nWith a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Both the text wording and a quote from the lead researcher suggest that the results of this meta-analysis are applicable to all women in labor, a conclusion that is not supported by the original research report. Additionally, the source declares, early in the release, that the results of the analysis \u201care compelling and strongly argue for a change in practice.\u201d Again, the limitations of the meta-analysis do not seem to warrant such prescriptive\u00a0language.", "answer": 0}, {"article": "\"Unfortunately, that is not the case.\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\n\"The basic assumption is that, after registration, the spatial relationships between the patient's head and the fiducial markers remains constant,\" said Patrick Wellborn, the graduate student who is making the presentation.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The news release maintains a restrained approach, with the exceptions of the headline and the lead. \u201cHow six cups of ground coffee can improve nose, throat surgery\u201d is vague and misleading, since there\u2019s no proven benefit yet. And it doesn\u2019t strike us as accurate to describe this as \u201cplopping six cups of coffee grounds on the heads of patients just before they are wheeled into the operating room to have nose or throat surgery.\u201d", "answer": 0}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nToday, the only reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline \u2014 \u201cA brain injury diagnosed with a single drop of blood\u201d \u2014 was among several examples of language in this news release that exaggerated the benefits of this test. Another was that patients will have \u201cNo more doubts!\u201d about whether they might have a concussion. It is not clear that this test will improve outcomes in any way.", "answer": 0}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nNormal cells are mostly spared.\n\"Most importantly, patients themselves have reported a better experience with less hair loss and improved quality of life,\" she said.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\nIn addition, 32 percent of the women receiving talazoparib had other side effects, compared with 38 percent of those on standard chemotherapy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "This trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nSpecifically, between May 2013 and June 2014, 68 eligible prostate cancer patients were identified and offered study participation, of which 45 consented (66 percent) to attend twice-weekly yoga classes of 75 minutes each, taught by trained Eischens yoga instructors within the Abramson Cancer Center.\nFurthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The lead sentence quotes researchers at the University of Pennsylvania stating that men with prostate cancer who are undergoing radiation therapy \u201ccan benefit from yoga.\u201d\u00a0 In her closing quote lead researcher Neha Vapiwala, MD, associate professor at the University states, \u201cWe offer several ways to enhance quality of life, minimize or reduce side effects of cancer and cancer treatment, and promote healing and recovery.\u201d\nBut nowhere in the news release are we given more than anecdotal evidence to support those assertions.\nThere was no data supporting the claim that more men than expected participated. Where did that idea come from? Given that the population was men with cancer one would expect them to be more\u00a0 open to alternative therapies.", "answer": 0}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nThe results were published online Jan. 30 in the Journal of Alzheimer's Disease.\nThere is no larger trial in the works yet, according to Scharre.\nThat included one who actually showed some improvements.\nThat patient was LaVonne Moore, 85, of Delaware, Ohio.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story draws from sources other than a Ohio State Wexner Medical Center news release.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There was a JAMA release on the study, but the story also appears to be solidly based on a presentation at a scientific society meeting and the JAMA article and accompanying editorial.\n\u00a0", "answer": 1}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\nBoth times the agency refused to even consider the application.\nThe clinical trial results haven't been great.\nThe agency still has nearly two more weeks to make a decision.\nSo they tried ataluren.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly does not rely on a news release.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. As noted above under disease mongering,we found some examples of exaggeration in the release.", "answer": 1}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\nThere were no measurable differences in weight or blood pressure measurements over the 16-week study period.\nWhile heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The tone of the release is carefully measured throughout, with the writer repeatedly using language like \u201cmight\u201d and \u201cappears to be.\u201d", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is enough original reporting here that we can be sure the story wasn\u2019t based entirely on a news release.", "answer": 1}, {"article": "\u201cAlthough it\u2019s very exciting, it is very early days,\u201d added Sha.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\n\"We do have a study with what we think is a commercially viable product that will start early next year,\" McCracken said.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\n\u201cThere is a theory that there is an inflammatory process that is driving the disease and the plasma is helping that,\u201d she said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to have relied on a news release. In this cast, that\u2019s unfortunate since a news release produced by Stanford University is more cautious and comprehensive in its detail than is this NBC story.\n\u00a0", "answer": 1}, {"article": "While they were eating the avocado-a-day diet, the volunteers saw their LDL go down by more than 13 points compared to their usual levels, Kris-Etherton\u2019s team reported in the Journal of the American Heart Association.\nThe Hass Avocado Board helped pay for the research, which was also funded by the U.S. government.\nRepeated studies have shown it raises the risk of heart disease.\nThey were less likely to have strokes or heart attacks, and they were less likely to die over a period of years than people who didn\u2019t get the extra oils.\nSaturated fat \u2013 the kind found in meat and butter \u2013 has a different chemical structure from the unsaturated fats found in plant products.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story clearly went beyond the news release. It included an interview with the researcher and brought in a significant amount of additional context from other diet studies.", "answer": 1}, {"article": "\"Although media coverage of the early release of data from the STAR trial suggests a clear 'winner' in raloxifene, the data from clinical endpoints and patient-reported symptoms suggest a less clear conclusion,\" Dr. William J. Gradishar and David Cella of Northwestern University wrote in an editorial in the medical journal.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story cites information from both the editorial that accompanied these studies as well as the researcher who presented the results at a professional meeting. It might have been helpful to note that neither the authors of the editorial nor the presenter appear to have any financial relationship with either drug manufacturer; this information was available in the published articles. ", "answer": 1}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\nTherefore investigators recommended that only patients who are younger than 76 years old, and who do not suffer from other health problems use FOLFIRINOX.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Not applicable. We can\u2019t be sure of the extent to which the story relied on any news release, as no one is interviewed.", "answer": 2}, {"article": "They received acupuncture twice a week for 30 minutes over four weeks.\nThe findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\nStill, \"our study shows that physicians and patients have an additional treatment for something that affects many men undergoing prostate cancer treatment and actually has long-term benefits, as opposed to more side effects,\" said lead author Dr. Hani Ashamalla, a radiation oncologist at New York Methodist Hospital, in a news release from the American Society for Radiation Oncology.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Mixed bag.\nThe story admits it drew its lead researcher quotes from a news release.\nBut it turned to an independent expert for analysis.\u00a0 Because that independent expert injected some questions about the limitations of the research, we\u2019ll award this a barely satisfactory grade.\nBut why wasn\u2019t the lead author himself interviewed?", "answer": 1}, {"article": "The fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\nBut two studies discussed at the oncology meeting found that patients who were considered Her2-negative even using both tests benefited from Herceptin.\nSo better ways are needed to determine who should be treated.\nThey are now classified as negative but might still derive some benefit from the drug.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a press release as several sources are cited.", "answer": 1}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nHoney is also known to have antioxidant and antimicrobial properties.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nMore than a third of American adults use some form of complementary or alternative medicine, according to a government report.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on any news releases.", "answer": 1}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\nFluorouracil has the advantage of being less expensive than imiquimod.\n\"Both creams have an equal cosmetic outcome and risk of local adverse events.\nOur evidence indicates that a personalized treatment approach is necessary,\" added Dr. Roozeboom.\nContact George Woodward at 1-215-605-3050 or g.woodward@elsevier.com to obtain copies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unsupported claims were made.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "A study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nThe men in this study \u2014 205 with confirmed BRCA1 or BRCA2 mutations and 95 who had tested negative for the mutations \u2014 were all offered annual PSA blood testing, and 24 who had raised PSA levels were given a follow-up biopsy.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Most of the information in the story about the study appears to come from this press release, including the sole quote:\u00a0\"Although these are early results, it appears that PSA screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition. This study provides support for continued screening in men with genetic mutations.\" While the story does add some great context about screenings and previous studies, it is hard to overlook this dependence on a press release.", "answer": 0}, {"article": "The ClinicalTrials.gov identifier for the Phase 2 study High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT-MS) is NCT00288626.\nOver years, the disease can worsen and shift to a progressive form.\nThree participants died during the study; none of the deaths were related to the study treatment.\nDr. Nash served as principal investigator of the HALT-MS study.\nNews releases, fact sheets and other NIAID-related materials are available on the NIAID website.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The tone of this news release is restrained, with no sensational language.", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We couldn\u2019t find a news release to compare with the story. But since no independent sources are quoted, we can\u2019t be sure the story didn\u2019t rely on a news release. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\nThe hope is to find more melanomas sooner.\nA computer compares these to a database of 10,000 archived images and recommends whether a biopsy should be done.\n\"Ultimately it's the responsibility of the dermatologist to use his clinical judgment to make the best decision.\nThis machine is there to help him, not replace him.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely on a news release.", "answer": 1}, {"article": "For most patients the cravings really do disappear.\nHere's how Hutcher does the surgery: first, he sections off a small pouch of the upper part of the stomach, which is then attached to a lower part of the small intestine, bypassing most of the stomach, so that there's not a lot of room for food.\nIt's pretty well known to doctors that the most successful treatment for obesity is surgery, especially the gastric bypass operation.\nAsked how many people gain the weight back, Dr. Hutcher tells Stahl, \"You know I think when you're dealing with an incurable disease that kills many people, if you have an 85 to 90 percent success rate, that's pretty darn good.\"\nBut here's something the medical world is just realizing: that the gastric bypass operation has other even more dramatic effects.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence the report is based on a press release. \nMany previous news reports have been done on the link between the surgery and reduced incidence of diabetes independent of weight loss, however. ", "answer": 1}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Although there are some similarities in wording between the story and this press release put out by Methodist Hospital, we didn\u2019t find any exact\u00a0duplication of text. And since the story\u00a0includes interviews with a researcher\u00a0and patient, we can be sure it didn\u2019t rely exclusively on the release for content.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\nThey compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "For more information, visit http://www.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\nMedical Cannabis Significantly Safer for Elderly With Chronic Pain Than Opioids, According to Ben-Gurion University of the Negev Researchers\n\nBEER-SHEVA, Israel...February 13 - Medical cannabis therapy can significantly reduce chronic pain in patients age 65 and older without adverse effects, according to researchers at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical Center.\nAbout American Associates, Ben-Gurion University of the Negev\n\nAmerican Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The title of the release, \u201cMedical cannabis significantly safer for elderly with chronic pain than opioids,\u201d goes far beyond what the study found. It implies this was a comparative study.\nIt\u2019s overreaching to imply\u00a0that cannabis is \u201csafe and efficacious\u201d in treating nearly a dozen conditions based solely on the self-reporting of a small number of subjects, and in an observational study that can not establish cause and effect.", "answer": 0}, {"article": "The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.\nPatients who experience signs or symptoms of lung damage (pulmonary toxicity) should stop using Rydapt.\nIn the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.\nWomen who are pregnant or breastfeeding should not take Rydapt because it may cause harm to a developing fetus or a newborn baby.\nAML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No unjustifiable language here.", "answer": 1}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"While more research is needed, the hope is such a tool could one day be used on the sidelines to help determine more quickly whether an athlete needs further testing.\"\nThe American Academy of Neurology, an association of 30,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care.\nVANCOUVER, British Columbia, April 13, 2016 /PRNewswire-USNewswire/ -- Mapping blood flow in the brain of athletes using an advanced form of ultrasound may make it easier to more accurately recognize concussions, according to a study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Although the text does not shy away from demonstrating\u00a0that the\u00a0technology under study does a better job of detecting changes in blood flow among concussed athletes than do other diagnostic strategies, it also offers cautionary comments that make clear the device is still very much in the testing phase.", "answer": 1}, {"article": "Achillion, one of the few companies developing hepatitis C therapies independently, plans to begin a mid-stage study this year to evaluate its proprietary doublet.\n(Reuters) - Achillion Pharmaceuticals Inc\u2019s experimental hepatitis C drug, when used with Gilead Sciences Inc\u2019s Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent years, with several companies including Gilead, AbbVie and Merck & Co Inc working on faster, more potent ways to cure the liver-destroying virus, which affects more than 170 million globally.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story takes a quote from this Achillion news release, but it alerts readers to the fact that the language came from \u201ca statement.\u201d Since no independent perspectives are offered, we can\u2019t really be sure to what extent this story relied on the news release, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "LOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nPatients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nAMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is little to go on to determine what source was relied on.", "answer": 2}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nIn addition to Rimer and Asplin, authors on the paper include Giannis Mpourmpakis and his graduate student, Michael G. Taylor, of the University of Pittsburgh; Ignacio Granja of Litholink Corporation, and Jihae Chung, a UH graduate student working in Rimer's lab.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release generally sticks to careful language about the potential benefits of hydroxycitrate, clearly noting that further studies are needed. However, the release would have been better if the cautionary notes about the need to do human safety and effective trials had been near the top, instead of buried at the bottom of the release.", "answer": 1}, {"article": "For now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nWeiner conducted much of the research leading to Amyvid's approval.\nThis is a way of getting closer to an answer,\" said Weiner.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nNo one wants to hear that he or she has Alzheimer's disease.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "To our knowledge, the story did not rely on a press release.", "answer": 1}, {"article": "In this study, researchers randomly assigned half of 263 healthy Swedish full-term newborns to have their cords clamped more than three minutes after birth.\nWhen separated by sex, only the boys showed statistically significant improvement.\nThe other half were clamped less than 10 seconds after birth.\nJaundice is treated with blue light therapy and rarely has serious complications.\nFour years later, the children underwent a series of assessments for IQ, motor skills, social skills, problem-solving, communication skills and behavior.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not rely solely on a news release.", "answer": 1}, {"article": "Influenza viruses have already developed widespread resistance to three commonly used flu drugs \u2014 amantadine, rimantadine and Roche AG and Gilead Sciences Inc\u2019s Tamiflu.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n\u201cTherapies for parainfluenza are urgently needed,\u201d Moscona, an expert on parainfluenza viruses, said in a statement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "       \n \nNot applicable because we can\u2019t be sure of the extent to which the story may have been influenced by a news release.\u00a0 We do know that the researcher\u2019s quote came from a statement, not from an interview. And the only other attributed comment came from a drug company spokesman. \n ", "answer": 2}, {"article": "(That\u2019s a high dose; a 3 oz.\nThese are questions Kwong and others hope to answer with more studies.\nThe 4g is a high dose; previous studies in which people were given 1g of fish oil were more inconsistent.\nThe remaining healthy tissue starts to compensate for the compromised tissue, but has to work harder to maintain the heart\u2019s normal pumping function.\nIt\u2019s the first encouraging strategy for protecting the heart a heart attack; the more remaining healthy tissue that can be saved, the stronger the heart will be.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to be based on a news release.", "answer": 1}, {"article": "The best results came from patients with the BRCA mutation: Their tumors didn\u2019t start to grow again for 21 months, on average, compared to 5.5 months for a control group that just received a placebo.\nWhile chemotherapy is still used as a first line of attack, PARP inhibitors are largely being studied as maintenance drugs.\nThe results were published this weekend in the New England Journal of Medicine.\nShe\u2019s launching a larger trial for further study.\nIt showed that patients with recurrent ovarian cancer treated with the drug got an extra 15 months without their disease getting worse, compared to a control group.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no indication\u00a0that this story relied on a news release.", "answer": 1}, {"article": "CDC recommends treatment of suspected cases of flu among pregnant women with antiviral drugs as soon as possible, without waiting for test results to confirm influenza.\nThe journal is an official publication of the Infectious Diseases Society of America (IDSA).\nPublished continuously since 1904, The Journal of Infectious Diseases is the premier global journal for original research on infectious diseases.\nThe findings also underscore the importance of flu vaccination for this risk group.\nIn the study, pregnant women hospitalized with severe flu illness were half as likely to have been vaccinated as women hospitalized with milder illness (14 percent vs. 26 percent).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t go overboard with unjustifiable language.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nA camera at the tip shows the inside of the gut, so that unusual cell clumps can be found and removed.\n\u201cThe idea that you\u2019re tailoring screening to age and some combination of risk factors is entirely reasonable,\u201d said Robert Smith, the director of cancer screening at the American Cancer Society.\n\u201cFrom a task force perspective, this article alone would not prompt us to look at the screening guidelines.\u201d\nDuring widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes several independent sources, the reader can assume that the story does not rely on a press release as the sole source of information.", "answer": 1}, {"article": "Probiotic organisms are non-pathogenic bacteria that, when present in the gut flora, are known to improve the overall health of the host.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nThe GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThis connection, named the \"gut-brain axis\" (GBA), allows for crosstalk between the endocrine, immune, and autonomic nervous systems.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Along with the unsubstantiated headline suggesting \u201cmillions\u201d of people who suffer with bipolar disease could be helped by probiotics, the release employs the pseudoscientific term \u201cgut-brain axis\u201d to suggest there are known connections between good and bad bacteria, microbial balance, and psychiatric mood disorders.\nBut without data, much of the language used throughout the news release is unjustified.", "answer": 0}, {"article": "MONDAY, March 19, 2012 (HealthDay News) -- New research finds that a minimally invasive surgical procedure to treat hernias results in less chronic pain and a faster recovery when compared to a traditional approach.\nAlmost all the patients were men, and their average age was around 55.\nIt can be done under local anesthesia.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nIt was developed in the 1990s, Brunt said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story wasn\u2019t based on a press release.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Identical phrases appear in the story and in the FDA\u2019s news release. The lack of independent sources also suggests that the author has relied on the press release as the only information source.", "answer": 0}, {"article": "The researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\nIn 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nIn addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\nIt is a future where Ben-Gurion U. invents a new world and inspires a vision for a stronger Israel and its next generation of leaders.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensational, unjustifiable language.", "answer": 1}, {"article": "MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nIn fact, nearly 3 percent of the patients died shortly after receiving the transplant, and those deaths were directly related to the transplant, the researchers reported.\nMost people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed the disease, the society says.\n\"It's important to select patients in such a way that they actually get well with the transplant.\"\nWithin 100 days of transplant, however, eight patients died (nearly 3 percent).\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story appears to go beyond any news releases we were able to find regarding the paper.", "answer": 1}, {"article": "LONDON (Reuters) - Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.\nAspirin, originally developed by Bayer, is a cheap over-the-counter drug used for pain and to reduce fever.\n\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nHis suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.\n\u201cYes, okay, it\u2019s a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "Any HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nThe researchers say the technology, although still in the early stages, could allow patients to regularly monitor their virus levels in a similar way to diabetes patients checking their blood sugar levels.\nLONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\nPublished in the journal Scientific Reports, results showed the stick test was 95 percent accurate over 991 blood samples, and the average time to produce a reading was 20.8 minutes.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Quotes were copy and pasted directly from the ICL press release, and we didn\u2019t detect any signs of original reporting. \u00a0\u00a0\nFrom the news release:\n\u201cHowever, monitoring viral load is crucial to the success of HIV treatment. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result. We have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\nAnd the Reuters news story:\n\u201cMonitoring viral load is crucial to the success of HIV treatment. At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine. \u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d", "answer": 0}, {"article": "Organizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing \u2014 but only if Lucentis were used.\nThe fourth group got laser therapy plus a sham injection.\nRetinopathy results from damage to the blood vessels in the eye.\nBut he said there were other factors as well, like a belief that Lucentis might have been the better drug.\nSo doctors can \u2014 and some already do \u2014 use the drug off-label for the diabetic condition.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\u00a0Does not appear to rely on a press release.", "answer": 1}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nIt may be that the vitamins contribute to high levels of folate.\nThe risk rose if the mothers or the children had a high-risk gene form.\nThe researchers collected blood from all family members to evaluate their genetic makeup.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story quotes an independent researcher and doesn\u2019t seem to rely excessively on\u00a0any news release.", "answer": 1}, {"article": "For more nutrition information and to access a vast collection of healthy potato recipes, please visit http://www.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\nToday, as the largest vegetable commodity board, the USPB is proud to be recognized as an innovator in the produce industry and dedicated to positioning potatoes as a nutrition powerhouse--truly, goodness unearthed.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\n\"Dietary habits established during childhood often transition to adulthood, so it is hugely important to encourage children to enjoy vegetables as part of the diet in order to reap the nutrition and health benefits provided by vegetables into adulthood.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline \u2013 and use of \u201cbest hope\u201d \u2014 is unjustified, as far as we can tell.", "answer": 0}, {"article": "Oct. 26, 2011 -- An experimental drug called briakinumab appears to be more effective than a standard medication for treating psoriasis, a new study shows.\n\"We in dermatology have never spoken about remission before.\nThose same results were achieved by about 10% to 20% of 163 patients in the methotrexate group.\nBut with this drug, the word 'remission' is on the table.\"\n\"Obviously, the price that this comes with is the increased rate of serious infections and cancers.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release steps over the line several times in its use of hyperbole, beginning with the headline, \u201cScalpel-free surgery proves safe, effective for treating essential tremor,\u201d that ignores the high proportion of adverse effects reported in the study and the limited time \u2014 12 months \u2014 that the study covered.\u00a0 Saying a procedure is safe without long-term studies is an exaggeration.\u00a0 Further on, subheads refers to it as a \u201cpioneering tremor trial\u201d and \u201cgroundbreaking research.\u201d", "answer": 0}, {"article": "Few of the programs studied, though, included exercise.\nAnd like most of the recent studies about the health effects of low-carbohydrate diets, \u201cthese are very short-term results,\u201d said Dr. Dena Bravata, an internist and research associate at the Center for Primary Care and Outcomes Research at Stanford University, who was not involved with this experiment but has conducted dietary studies.\n\u201cIt took people less time to lose 10 pounds\u201d on a high-fat diet-and-exercise program, about 45 days on average, than the 70 days it took for those who exercised and followed a high-carbohydrate, low-fat diet constructed using guidelines from the American Heart Association, said Kerry J. Stewart, director of clinical and research exercise physiology at Johns Hopkins University School of Medicine and lead author of the report.\nAt the start of the program, the volunteers all had healthy blood vessels, as determined by a blood-pressure cuff test in which researchers tighten the cuff, release it and track the resulting gush of blood to the volunteers\u2019 fingertips.\nThe data being presented on Friday represent only interim results from a longer-term, larger study, Dr. Stewart pointed out.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure of the extent to which the story may have relied on a news release.\u00a0 We do know that that the work hasn\u2019t even been presented at a conference yet, much less published.", "answer": 2}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no obvious evidence the story relies on a press release. ", "answer": 1}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\n\"And all the drinking variables changed in the right direction.\"\nAll volunteers were encouraged \u2014 but not required \u2014 to stop drinking.\nThe study followed 371 heavy drinkers for 14 weeks.\nThe drug, Topamax, works in a different way than three other medications already approved for treating alcoholism.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a press release.", "answer": 1}, {"article": "Greenwood says he'd like to see many more patients try diabetes prevention programs.\nThere is some evidence that these kinds of programs are working.\nHe began to weigh himself daily.\nEven though they never met in person, they bonded.\nHe tracks his movement withe a wearable electronic device.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article does not appear to rely on a news release.", "answer": 1}, {"article": "Vincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nThat requirement has hobbled other alternative treatments, including the herb red clover and vitamin E supplements.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\nThe study of acupuncture as a remedy for hot flashes was sparked by reports from women who had undergone the ancient Chinese therapy for other problems and reported that their hot flashes seemed to moderate.\nAcupuncture involves the use of hair-thin disposable metallic needles inserted into various parts of the body; treatments are supposed to be painless and are designed to correct energy imbalances.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this story relied on a news release. ", "answer": 1}, {"article": "To be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nBut the latest batch of evidence deserves a closer look.\nEven a baby aspirin might be enough.\nThe biggest is stomach bleeding, although it also raises the risk of brain hemorrhage.\nAnd the researchers were able to gather more information about cancer deaths for up to 20 years after those studies ended about nearly 13,000 people.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to rely on a news release.", "answer": 1}, {"article": "The classic nicotine buzz occurs when the molecule travels in the bloodstream across the \"blood-brain barrier\" to reach specific receptors in the brain.\nThe total number of subjects in the trial is expected to be about 300.\nThis lack of positive physiological reinforcement for smoking is believed to reduce the nicotine craving that causes smokers to fail in their efforts to quit.\na decade ago for smoking cessation.\nThe current study will test vaccine dosages and sequences of four or five shots; some subjects will get a placebo.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It appears that the story does not rely solely on a press release for information used in the story. ", "answer": 1}, {"article": "I was glad it was done a week before and not the same day as the lumpectomy surgery.\nBecause this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nWire localization requires a high degree of coordination between radiology and surgical scheduling, which can lead to delays between placement of the wire and surgery, often requiring a woman to wait long periods of time with the wire in her breast.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. The benefits claims are carefully worded and provide a positive view of the technology. Statements such as: \u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d are technically correct when viewed as a potential. However, the release is consistent in its suggestion that the technology is a clear advance over existing methods, without offering any comparisons or data.", "answer": 1}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nBut there's a whole bunch of reasons why Americans' postures \u2014 and the shape of their spines \u2014 may be different than those of indigenous populations, he says.\n\"If you have a lot of fat built up in the belly, that could pull your weight forward,\" Mummaneni says.\nLost Posture: Why Some Indigenous Cultures May Not Have Back Pain\n\nEditor's note, June 10: We have added an acknowledgement of several sources that Esther Gokhale used while developing her theories on back pain.\nIt's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story isn\u2019t linked to any news release that we could find, and includes enough original reporting that we can be sure it wasn\u2019t based entirely on a release.", "answer": 1}, {"article": "The study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nThis article has been updated to include additional comment from Kathryn Cullen.\n\"The field is in need of new treatment options.\nDuring a two-week period, the researchers gave them six ketamine infusions.\nFive of the participants met the criteria for clinical response and remission.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied on a news release.", "answer": 1}, {"article": "Iron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nThen, moments after birth, that cord is severed.\nThe benefits of those extra few minutes may last a long time.\nCutting the cord is a momentous event in a baby's life.\nBabies who are anemic often appear tired and pale.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story quotes an additional source and did not rely on a news release.", "answer": 1}, {"article": "A video of him walking with and without aid of the system can be found here: https:/ .\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\n\"Both guys were taking steps the first time we turned the systems on,\" said Ron Triolo, a professor of orthopaedics and biomedical engineering at Case Western Reserve and executive director of the Advanced Platform Technology (APT) Center.\nIn each patient, \"the pulses are sent in a pattern that is close to how normal muscles work,\" said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational language. However, the headline could easily mislead casual readers into thinking that nerve stimulation could help all MS and stroke patients improve their ability to walk, when in fact this specific technology was tested on just two patients.", "answer": 1}, {"article": "In clinical trials, a plant-based diet lowers total cholesterol by 12.5 mg/dL.\n\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\n\"The first place to start is by building meals around nutrient-packed, plant-based foods, which fit into nearly every cultural template, taste preference, and budget.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Overall, the release did not raise any of our red flags for sensational language. However, caution should be exercised before making statements such as that found in the physician testimonial:\n\u201cWithin the first month of making the dietary change, he effortlessly lost 10 pounds.\u201d\nLosing weight by making and sustaining dietary changes is rarely an\u00a0effortless\u00a0process. It takes time, commitment, and often, social support from family and friends. This characterization can be misleading for readers.", "answer": 1}, {"article": "FDA advisers urge approval for first gene therapy for inherited disease\nThis type of cancer begins in the immune system and can be fast- or slow-growing, the FDA noted.\n\u201cThe doctors were saying, 'Go see an attorney and get your life in order,' \" the 64-year-old Realtor recalled.\nIn late August, the FDA cleared the first CAR T-cell therapy, which is designed for children and young adults whose leukemia doesn't respond to standard treatments.\nThe treatment is for adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment, such as chemotherapy and bone-marrow transplants.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Many of the facts and some of the quotes in the story come from the news release put out by the FDA, but there were enough unique details to give the story a pass in this category.", "answer": 1}, {"article": "Children who took vitamin D had a significantly lower BMI, the researchers found.\nDr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nAccording to findings presented at the European Society of Endocrinology annual meeting in Barcelona, individuals with higher levels of total body and abdominal fat appeared to have lower levels of vitamin D.\n\nRachida Rafiq, the lead author of the study told Newsweek at the time: \"Our results are significant as vitamin D deficiency and obesity are very common problems in our society nowadays,\" she told Newsweek, and argued that it is an important potential relationship to explore.\nRelated: Household cleaning products might be making your children fat\n\nIn what is believed to be the first study to investigate the links between vitamin D supplementation and the weight and health of obese children and adolescents, researchers from University of Athens Medical School and Aghia Sophia Children's Hospital, Athens, recruited 232 particpants.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Some quotes used in the story match word-for-word what we found in a press release published by the European Society for Pediatric Endocrinology. Although there was outside expert commentary woven into the story, not mentioning or even linking to the release is a no-no if you are trying to be transparent about sourcing and helpful to readers.\nFor example, this quote appears in the Newsweek story, and is not attributed to the news release:\n\u201cThese findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d", "answer": 0}, {"article": "\"With regard to the use of dexamethasone, more research is needed to confirm our finding, preferably in multicenter trials, but there are strong indications that it can be beneficial in many cases.\"\nIf so, the use of an anti-inflammatory drug may have a protective effect,\" said Maria Jos\u00e9 Carvalho Carmona, a professor of anesthesiology at the University of S\u00e3o Paulo's Medical School (FM-USP) and principal investigator for the study.\nIn the fourth group (superficial anesthesia with dexamethasone), the incidence of POCD was 15.3% immediately after surgery, but after six months the pre-operative cognitive status was restored in all patients.\n\"The tests available today are either too time consuming or quick but unreliable,\" Carmona said.\nThe problem has become more frequent as the population ages and also as a growing number of older adults undergo surgical procedures made possible by more advanced medical technology.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release uses responsible language to discuss the findings, although it could have been more clear about the preliminary nature of the work. A larger study is almost certainly called for on this intervention.\nWe do have some concerns over the use of the acronym \u201cPOCD\u201d to describe cognitive dysfunction following anesthesia. It appears to be a coined medical term that few clinicians use.", "answer": 1}, {"article": "(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\nAdmissions for heart attacks were nearly 8 percent lower in counties with restrictions.\nSimilarly, admissions for strokes were about 4 percent lower in counties with restrictions, but that finding could be due to chance.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\nWhile admissions for heart attacks and strokes fell after 2002 in all the counties, the drop was more substantial in those that enacted trans fat restrictions, the authors found.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release was made available\u00a0by Yale University, but this story offers a level of detail that far exceeds that.\n\u00a0", "answer": 1}, {"article": "Jan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nIBS is considered a functional gastrointestinal disorder without a known physiologic cause, with the symptoms recurring and often worsened by stress.\nThe stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on a news release.", "answer": 1}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n\"Tucatinib could be a substantially practice-changing drug,\" Borges says, meaning that in addition to the drug's current investigations as a third-, fourth-, or more-than-fifth-line treatment, she envisions its use sooner in the arc of breast cancer treatment and with far more patients.\n\"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments,\" Borges says.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The use of unjustifiably glowing language arguably is the news release\u2019s most serious\u00a0flaw. In particular, the subhead of the release quotes Dr. Borges as saying, \u201cThere are women who are alive today because of this drug.\u201d Later in the release, she predicts that tucatinib \u201ccould be a substantially practice-changing drug.\u201d While either statement could be true, drawing such sharp conclusions from evaluations of 35 women, only three of whom actually experienced tumor shrinkage, seems premature.\nIn addition, the investigator is quoted saying, \u201cAnd it\u2019s going to be an especially important drug due to its ability to control brain metastases\u201d\nIt\u2019s important to note the comments about crossing the blood brain barrier that come from the \u201cTranslational Relevance\u201d section of the study. The authors note that in preclinical studies with intracranial tumor models, mice treated with the investigational drug combined compared with 2 other oral agents (lapatinib or neratinib) showed a survival benefit when each drug was given at maximum dose. They do not note any study or evidence showing that this investigational agent has shown benefit in terms of treating brain metastasis in human patients, so that language in the release also appears unjustified.\nBecause it seems tucatinib would be used for a particularly vulnerable group of women \u2014 those diagnosed at younger ages and with more aggressive and difficult-to-treat cancers \u2014 it seems especially important that those writing about the drug exercise caution and avoid overplaying study results.", "answer": 0}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe rate was 26 percent lower in counties with screening.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nIt\u2019s clear that the story was not based on a news release.", "answer": 1}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\nStill, the trend seems to be going strong.\nThe other \u2014 which was also missing a placebo group \u2014 involved just seven patients and showed only short-term improvement in symptoms.\nIt\u2019s very relaxed, not like a spa.\nA longitudinal study would be needed to back those claims with evidence, she added.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not appear to rely on a news release, and quoted independent sources.", "answer": 1}, {"article": "She told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nFor the first time, researchers have shown that gene therapy can be used to improve vision for blind children and young adults.\nBefore the surgery, she could only make out the biggest letters on the first few lines.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We can\u2019t be sure if the story relied solely or largely on a news release.\u00a0 But we do know that the segment did not include any perspectives from independent experts unaffiliated with the experiments. ", "answer": 2}, {"article": "Our study sheds light on how this interaction can be modified by breastfeeding.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t employ sensationalistic language, however, as noted above, some statements may not have been justified based on the other information provided. \u201cInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed [sic]\u201d and\u00a0\u201cOur study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life.\u201d What the study did show was a 27 percent relative risk reduction in children who were breastfed as compared to a group who were not.", "answer": 1}, {"article": "The drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nThe increased risks, while double in relative terms, are small.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is independent reporting and no evidence that information in this story is taken directly from a press release.", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nIt is a characteristic disease of developed countries, associated with pollution, air conditioning, the use of contact lenses, refractive surgery and continued use of computers.\nHowever, the main treatment consists of artificial tears, in the form of drops, gel or creams.\nThe therapeutic application of targeted siRNAs is booming given the specificity of gene silencing for a particular protein in a given tissue and the lack of side effects.\nPrevalence is between 10% and 20% among people aged 50 or over, and it is more frequent in womeni,ii.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The unjustifiable use of the terms \u201cdry eye disease\u201d and \u201cdry eye syndrome\u201d have already been addressed under the Disease Mongering criteria.", "answer": 1}, {"article": "In 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nPain relief was sustained in six patients who continued treatment for one year.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nSatisfactory relief was considered a 40 - 69 percent reduction in pain scores (6 patients) and excellent relief, pain reduction of 70 percent or more (5 patients).\nNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There wasn\u2019t any evidence of \u2018over-the-top\u2019 exaggeration of the findings of this study.", "answer": 1}, {"article": "For more information, go to www.bayer.us.\n\"Data show that the use of effective, long-acting birth control methods including intrauterine devices \u2013 or IUDs \u2013 have helped to reduce unintended pregnancies in the United States but we still have a long way to go,\" 2 said Anita L. Nelson, M.D., Professor and Chair, Obstetrics and Gynecology at Western University of Health Sciences, Pomona, Calif. \"Kyleena is highly effective at preventing pregnancy and may be an appropriate choice for women who want a low-dose, non-daily birth control method.\"\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\n\"With the approval of Kyleena, women have an important new birth control option that provides pregnancy prevention for up to five years,\" said Dario Mirski, M.D., Senior Vice President and Head of Medical Affairs for the Americas, Bayer.\nThe use of long-acting reversible contraception (LARCs) has increased nearly five-fold in the last decade.3\n\nBecause Kyleena slowly releases levonorgestrel into a woman's uterus, only small amounts of the hormone enter the blood.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in sensationalistic language.\nThe release may be slightly out-of-bounds, however, when it states, at the top, that \u201cKyleena offers women an important new long-term, reversible contraception option.\u201d\u00a0 Who decides what makes something \u201cimportant\u201d? It\u2019s a tricky question. Based on the limited information in the release, it\u2019s not clear that the term applies here or that the product offers significant differences from other products already on the market.", "answer": 1}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nLow testosterone is common in men with COPD and may worsen their condition.\nUTMB is a part of the University of Texas System and a member of the Texas Medical Center.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no examples of egregious and unjustified language here.", "answer": 1}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nIt aims to charge up the patient's immune system to attack cancer cells and halt their out-of-control growth.\n\"Each article that shows clinical activity is giving us a piece of the puzzle\" that will make it safer and more effective, he said.\nThis type of \"adoptive immunotherapy\" could be effective against a wide range of cancers, Yee said.\nSeveral independent researchers said the study results were promising.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "There aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nAlso, there was limited research on long-term results.\nThe two reports were published online Jan. 17 in the journal Pediatrics.\nThese days, the procedure is done 20 percent of the time for infections and 80 percent of the time for sleep problems, according to the academy.\nBy the third year, there was no clear benefit in terms of the number of throat infections.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to be based on a news release.", "answer": 1}, {"article": "He points to a recent meta-analysis published in the journal Addiction that concluded that naltrexone helped reduce heavy drinking and cravings for alcohol.\nThe center provides outpatient mental health and substance use treatment services.\nThat was exactly John's experience.\nBut they are substantially underused, according to the review.\nThe drug seems to curb the euphoric and sedative effects of opiates in the brain.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "\"This study highlights the collaborative spirit of academic medicine, and how our rheumatology and bariatric surgery researchers worked together to not only help our patients directly, but inform the medical community at large,\" says study co-author Jose U. Scher, MD, assistant professor of rheumatology and co-director of the NYU Langone's Psoriatic Arthritis Center.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nPatients were on average monitored for more than six years, with an average excess weight loss of 46.2 percent body weight.\nThe research team compared their patients' symptoms from before and after undergoing bariatric surgery.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The language is generally appropriate, and hasn\u2019t exaggerated\u00a0the effects of the bariatric surgery.", "answer": 1}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\nAll the mechanisms are not understood yet, but they may be linked to compounds forming during the fermentation process.\nFor further information, please contact:\n\nJyrki Virtanen, PhD, Adjunct Professor in Nutrition Epidemiology (principal investigator).\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "No overtly unjustifiable language was used.\nWe appreciate mention of the fact that the possible mechanisms for explaining the study\u2019s findings are not completely understood.", "answer": 1}, {"article": "Twenty-one patients resumed regular diets the day after surgery.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRenal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "\u201cRemoval of complex renal tumors performed safely by robotic surgery in selected patients,\u201d trumpets the headline. But nowhere do we learn what \u201csafely\u2019 means.\nThe lede says that \u201crobotic\u00a0nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience,\u201d but then fails to tell us what \u201cadequate robotic experience\u201d means.\nThat is a fair question, given that 32 cases were performed in nine centers, and at least one of the surgeons was responsible for 10 procedures. That leaves 22 for the other eight, or fewer than three per surgeon over a time span that began in 2008 and is only now being reported.", "answer": 0}, {"article": "If the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\nThe condition is poorly understood and somewhat vaguely defined, so estimates are not very precise.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nSome drugs that treat the pain, including opiates, can make the constipation worse, he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Since the story includes interviews with two experts \u2014 an IBS expert who consults for the drug manufacturer and the company CEO \u2014 we can be sure the study wasn\u2019t based entirely on a press release.", "answer": 1}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\nHis second marriage, to a woman who herself suffered from chronic depression, came undone within a year of his initial TMS sessions.\nPeople close to him questioned whether the risk was worth it.\n\u201cPerhaps I was hearing music pure and true, without the distorting lens of autism.\u201d\n\nOther striking changes in perception and mood soon followed.\n\u201cAnd what I wrote about in the book isn\u2019t 10 percent of what they\u2019re doing now.\u201d\n\n\u201cSwitched On\u201d ends in 2013.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story was obviously written from an interview of the author and his doctor. It did not rely on a news release.", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nVarious statements in this release and to be made on the conference call are \"forward-looking statements\" under the securities laws.\nThere are no adequate and well-controlled studies of HETLIOZ\u00ae in pregnant women.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t engage in blatantly unjustifiable language.  ", "answer": 1}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The headline\u2019s use of \u201cmay soon reverse vision loss,\u201d Svendsen\u2019s quote saying they\u2019re \u201cclose to a time\u201d of treating humans, and the cavalier referral to the \u201cnext steps\u201d without explaining that means many more years of study, all support a rating of unsatisfactory in this category.\u00a0 Anytime a news release raises hopes for treatment of a now-untreatable disease, it has to live up to those expectations. \u00a0This one didn\u2019t.", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no evidence that this article relied on a news release.", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- A minimally invasive treatment for enlarged prostate that limits blood supply to the prostate seems to be just as effective as surgery but without the risk of debilitating side effects, such as impotence and urinary incontinence.\nThe procedure is performed under general anesthesia and involves a hospital stay.\nThe U.S. National Institutes of Health has more on enlarged prostate.\nAfter nine months, none had experienced sexual dysfunction and 25 percent still reported improvements.\nBut other experts aren't so sure.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely solely on a news release.", "answer": 1}, {"article": "Three trials had used zinc acetate lozenges and found that colds were shortened on average by 40%.\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on sensational or unjustifiable language. However, it comes close when the study author states that there\u2019s no justification for the popular phrase,\u201dthere is no cure for the common cold\u201d because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\u201d A 30 percent reduction in cold duration is not necessarily a cure.", "answer": 1}, {"article": "\"The hope for neurofeedback is that after training ends, the benefits that resulted from training will persist -- that in some sense there's been more enduring change in the child's ability to focus and attend and to regulate their behavior,\" he says.\nAnd one chapter of the book is devoted to neurofeedback.\nHe wasn't doing his homework.\nThe study used a video game involving race cars.\nThe results should be out within a few weeks, Arnold says.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story does not appear to be based on a news release.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nIt further demonstrated that four or five laser therapies may be superior in lowering the intensity of GSM symptoms compared with three laser therapies in both short- and long-term follow-up.\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\nIn the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release is unjustified in claiming that this observational study demonstrates effectiveness. It made the claim in the following paragraph:\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness. It further demonstrated that four or five laser therapies may be superior in lowering the intensity of GSM symptoms compared with three laser therapies in both short- and long-term follow-up.\nThe last paragraph of the release somewhat moderates the hearty endorsement of the therapy.", "answer": 0}, {"article": "Cassandra Quave, an Emory University scientist who studies how indigenous people use plants in healing practices, said researchers pulled apart the chemical ingredients of the berries and tested them in mice infected with these superbug strains.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There appear to be a few original quotes in the Post story, not found in the news release. But story doesn\u2019t provide much beyond the information that\u2019s in the news release, and in fact has verbatim quotes from the lead researcher\u2013which aren\u2019t attributed as coming from the news release. Example:\nThis passage from the news release:\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of a patient.\u201d\nalso appears in the Post story:\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.", "answer": 0}, {"article": "Results of the regenerative medicine study published in the journal Nature Nanotechnology.\nWe have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nThis cargo, when delivered using the chip, converts an adult cell from one type to another, said first author Daniel Gallego-Perez, an assistant professor of biomedical engineering and general surgery who also was a postdoctoral researcher in both Sen's and Lee's laboratories.\nOur technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nResearchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "Use of the word \u201cbreakthrough\u201d in the release is unjustifiable. The breakthrough status in treating humans hasn\u2019t been established (or tested) and so the headline is misleading.\u00a0The title of the letter from which the news release is drawn is more restrained but very technical: \u201cTopical tissue nano-transfection mediates non-viral stroma reprogramming and rescue.\u201d The release should have been headlined with something between the two extremes that also highlights that this was animal research.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that this story involved independent enterprise reporting.", "answer": 1}, {"article": "\"The positive effects of bariatric surgery on health outcomes -- such as diabetes and cardiovascular disease -- are reasonably well-studied, but less is known about the effects on pregnancy and [post-delivery] outcomes,\" Johansson pointed out.\nAdditionally, the surgical group experienced a slight bump in the rate of stillbirths, the study found.\nContinued weight loss may affect fetal nutrition and could influence growth.\"\nThe surgical group was also much less likely to give birth to larger-than-normal babies.\nThey recommended any pregnancy after weight-loss surgery be considered high-risk and receive stricter monitoring.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article goes beyond any press release.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nThe associated pain can last months or even years.\nThe new study is published in the Journal of the American Medical Association.\nCalled Zostavax, the shingles vaccine is made by Merck.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story does not appear to rely on a news release.", "answer": 1}, {"article": "The recommendations also support the position of the American College of Cardiology and the American Heart Association, which in 2013 radically shifted their advice from suggesting that doctors focus on the level of a patient\u2019s low-density lipoproteins (LDL) or \u201cbad cholesterol\u201d to looking at a more comprehensive picture of risk based on things such as weight and blood pressure, as well as lifestyle factors.\nThey are more likely to not only get to the hospital and survive until they are discharged but also survive in greater numbers a year after their hospitalization than those who do not use statins.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\n\u201cIn deciding on any therapy, it is important to understand the risks and benefits, particularly for healthy people,\u201d they wrote.\nIt is also slightly more conservative when it comes to determining the benefits of taking the medications, which include Lipitor, Crestor and Zocor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The presence of outside critique of these recommendations suggest there was a low reliance on the news release.", "answer": 1}, {"article": "\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\n\"This presents an unprecedented opportunity for informative early detection of pancreatic cancer and in designing potential curative surgical options.\"\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story quotes just one source, the chair of MD Anderson\u2019s Cancer Biology department (the institution that issued a news release for the study), and those quotes can be found in the news release, we believe the story relied too heavily on the release.", "answer": 0}, {"article": "Hamilton, ON August 11, 2016 - A study led by McMaster University researchers has found that, contrary to recent reports, flu nasal sprays provide similar protection against influenza as standard flu shots.\nThis study was funded by the Canadian Institutes for Health Research.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nOur trial showed no difference between the two in protecting entire communities.\"\nThey are also looking at the effect of repeated vaccination of children.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release does not use any unjustifiable language.", "answer": 1}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nA newer version, one coated with zotarolimus, fell short, the study found.\nThe trial was partially funded by Medtronic, maker of the zotarolimus-eluting stent.\nFor more information on stents, visit the U.S. National Library of Medicine.\n\"There has been great interest in developing stents coated with alternative drugs and different polymers,\" he explained.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "We didn\u2019t find evidence that this article relied on a news release.", "answer": 1}, {"article": "Potluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n\"We need to further investigate the reasons for patients with high cholesterol having improved mortality in four of the most common cancers,\" said senior researcher Dr. Rahul Potluri, a clinical lecturer at Aston University School of Medicine in Birmingham.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\nAfter adjusting for factors that might play a role in dying, such as age, gender, ethnicity and common causes of death, the researchers found those taking statins lived longer than those who were not taking them.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because the story includes quotes not found in the news release, this is satisfactory. But it is ironic that a closer reading of the news release might have helped the authors avoid a mistake.", "answer": 1}, {"article": "The author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nThe research was paid for by the Danish government and private foundations.\nThe results were published in The New England Journal of Medicine.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This story did not rely on the news release.", "answer": 1}, {"article": "Previous studies have found women's monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues.\n\"This result emphasizes the need for gender-specific programs to quit smoking, as well as taking into consideration a menstrual cycle phase during addiction treatment in women,\" the researchers conclude.\n\"One of the factors contributing to these differences may be that women crave cigarettes more than men and that their desire to smoke is influenced by hormonal fluctuations across the menstrual cycle.\"\n\"While overall more men than women smoke cigarettes, women and girls take less time to become dependent after initial use and have more difficulties quitting the habit,\" the researchers write in their study.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The spin that\u2019s prevalent in this story probably originated with this press release headlined, \u201cWomen, quitting smoking for New Years? Time it with your period!\u201d However, the story includes quotes from the original study, so it appears that the press release was not the only source of information used for the story. We\u2019ll call this satisfactory.", "answer": 1}, {"article": "Drs.\n\"We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,\" Dr. Arterburn said.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\nResearch at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression\n\nSEATTLE--Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.\n\"A large body of evidence indicates no difference in how effectively the newer antidepressants improve people's moods,\" said Dr. Arterburn's coauthor Gregory Simon, MD, MPH, a Group Health psychiatrist, GHRI senior investigator, and research professor in psychiatry and behavioral sciences at the UW School of Medicine.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release doesn\u2019t rely on unjustifiable language. We would underscore the study author\u2019s comment that \u201cbupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese\u201d by adding that each individual needs to be evaluated for their symptoms with a medical professional making a recommendation on the appropriate drug therapy.", "answer": 1}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nAs its name implies, virtual colonoscopy is way to survey the colon without actually using a scope.\nThe images can be viewed as two dimensional CT scans, which display any possible abnormalities protruding from the lining of the colon.\nIn McHugh\u2019s survey, hospitals reported that these patients make up the bulk of their use.\nWhile the virtual colonoscopy does not require the sedation and insertion of a scope that colonoscopy does, it involves exposure to a small amount of radiation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Does not appear to rely on a news release.", "answer": 1}, {"article": "For more information about Red Journal, visit www.redjournal.org.\n\u201cWhile additional study and longer follow-up are necessary to confirm the optimal dose for single-fraction HDR brachytherapy, we are optimistic that the single-treatment approach can eventually become a standard practice for prostate cancer treatment.\u201d\n\nFor more information or a copy of the full study, contact ASTRO\u2019s media relations team at press@astro.org.\n\u201cIt is becoming apparent that patients may be treated definitively for their prostate cancer in as little as a single day with a minimally invasive outpatient procedure,\u201d said lead study author Daniel J. Krauss, MD, a radiation oncologist at Oakland University\u2019s William Beaumont School of Medicine in Royal Oak, Michigan.\nThe study is available online in the International Journal of Radiation Oncology \u25cf Biology \u25cf Physics, the flagship journal of the American Society for Radiation Oncology (ASTRO).\n\u201cThis study illustrates that a potentially curative dose of radiation may be delivered safely to the prostate entirely in a single administration,\u201d said Dr. Krauss.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release detracts from the actual study when it states that the research \u201cillustrates that a potentially curative dose of radiation\u2026\u201d \u00a0This seems unjustified in the context of the trial. Is one ever really \u2018cured\u2019 from prostate cancer?\nGiving caveats, yet dropping the line that \u201cthe single-treatment approach can eventually become a standard practice for prostate cancer treatment,\u201d seems premature.\nUrologist Willet Whitmore, MD, a founder of the urology oncology sub-specialty, spoke about localized prostate cancer cures this way:\u00a0\u201cIf treatment for cure is necessary, is it possible? If possible, is it necessary?\u201d", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story is about what appears to be a corporate-sponsored presentation at the World Sleep Congress.\u00a0 While this is not technically a news release, readers should know that it is somewhat comparable.\u00a0 Until more work is done and peer-reviewed, they may not be getting the entire picture.\u00a0 See our primer on some of the pitfalls of reporting news from scientific meetings.", "answer": 2}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\nThe study led by researchers at the Perelman School of Medicine at the University of Pennsylvania is the first to show that lisdexamfetamine (LDX) improved subjective and objective measures of cognitive decline commonly experienced in menopausal women.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "As noted above, we don\u2019t think it\u2019s well documented how \u201ccommonly experienced\u201d these cognitive complaints really are, to the point they interfere with life or functioning. However, since we\u2019ve already dinged the story for that problem and there aren\u2019t any egregious overstatements, we\u2019ll award a Satisfactory grade.\n\u00a0", "answer": 1}, {"article": "This study received funding from the Divers Alert Network and U.S.\n\"It appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\"\nIt dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\n\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nThe drug -- best known as Viagra\u2122 -- is normally used for treatment of male impotence, but also for pulmonary arterial hypertension.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "We found no language in the release that was clearly out of bounds. As noted above, however, we\u2019re concerned that cautionary language is overwhelmed by an enthusiastic testimonial from a swimmer who believes she has benefited from using the drug.", "answer": 1}, {"article": "And in an earlier Lilly-sponsored phase-3 trial, ixekizumab was shown to be effective for psoriatic arthritis patients who had not yet been treated with biologic drugs such as TNF inhibitors.\nIxekizumab works by blocking IL-17.\nGenovese has served as a consultant to Lilly.\nThe two syndromes differ, though, in their constellation of symptoms.\nStanford\u2019s Department of Medicine also supported the work.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "There are no examples of unjustified language.", "answer": 1}, {"article": "(\u201cEnjoyed\u201d?\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nBut in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity.\n\u201cOur study in a mouse model is important because we can take all those effects out of the equation,\u201d Waterland said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "This brief story is highly reliant on a news release. \u00a0The reporter has made no obvious attempt to contact the researchers for further information or to obtain reactions from other scientists.", "answer": 0}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\u201cPeople were planning their lives around hemophilia, and now they are doing activities that they weren't before,\u201d George said.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nAnd its effects lasted; after a year and a half, the longest patient follow-up, the therapy was continuing to work.\nIn addition, he said, researchers need to find ways to provide the therapy to a broader group of people, including children, and to figure out how to reduce the costs involved.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "A news release issued by Children\u2019s Hospital of Philadelphia did a good job of describing this study; the Post story could have picked up more of the salient details from that text but reveals independent reporting nevertheless by including sources not connected to the study.", "answer": 1}, {"article": "Analytics firm GlobalData has forecast that CGRP antibodies will generate combined sales of $4 billion by 2026.\nSimilar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\n\u201cThis is a trial in really difficult to treat patients,\u201d professor Uwe Reuter, trial investigator and managing medical director at Charit\u00e9 Universit\u00e4tsmedizin in Berlin, told Reuters in a telephone interview.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\nAimovig has the \u201cpotential to help fill treatment gaps in more difficult patient populations whose migraine has not been adequately managed with current therapies,\u201d Sean Harper, executive vice president of research and development at Amgen, said in a statement.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "While most of the information in the article is taken from this news release, the story is transparent about this. It also includes quotes from a telephone interview with the study\u2019s lead investigator, so we can be certain that at least some original reporting went into the piece.", "answer": 1}, {"article": "She worries about the small chance of benefit in light of the larger chance of finding and treating a cancer that did not need to be treated.\nWhen the study was planned, the scientists expected that screening would be even more effective than it was in studies from decades ago.\nAfter all, mammography had improved and, in Norway, each mammogram was independently read by two radiologists, which should make it less likely that cancers would be missed.\nIn the study, which is continuing, women were followed for a maximum of 8.9 years.\nAnd 5 to 15 of those women would be treated for cancers that, if left alone, would have grown so slowly they would never have been noticed.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "\n\n\nThe story includes comments from several sources and does not appear to rely on a news release.", "answer": 1}, {"article": "The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.\nThe new PSA test is given twice a year, along with a digital rectal exam to determine the size of the tumor, and a yearly biopsy.\nThe presence of circulating cells can indicate spread of the cancer to other parts of the body, but they are so rare that they are invisible to current technology.\nThe new test measures blood levels of three different types of PSA.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear that the story relied solely on a news release. ", "answer": 1}, {"article": "Researchers have found that delivering a fecal microbiota transplant (FMT) in a pill\u2014a poop pill, basically\u2014is no worse than a similar procedure done with a colonoscopy.\nThe transplants work by replacing those \u201chealthy\u201d bacteria.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nBut most importantly, the study found no difference in effectiveness between the two therapies.\n\u201cStool is such a complex mixture.\u201d\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It does not appear to rely on a news release.\n\u00a0", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nThese factors may also have a biological impact, he added.\nIn addition, the researchers asked the participants questions about sleep time, depression, insomnia, screen time and stress.\n\"Anyone who has ever tried to lose weight probably could have said much the same from personal experience.\nAnd the extra calories mostly came from saturated fat, which can spell trouble for waistlines.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "Santen and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\nFollow us on Twitter at @TheEndoSociety and @EndoMedia.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\n.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The release did not use unjustifiable language.", "answer": 1}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nThe study included 15 healthy participants who took part in six sessions.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\n\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release.", "answer": 1}, {"article": "For more information visit http://www.\nMore than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.\nThe survival benefit was more pronounced in patients whose tumours had tested positive for human papillomavirus (HPV).\nThese patients survived an average of 9.1 months with nivolumab and 4.4 months with chemotherapy.\nAfter one year of the study, 36 per cent of patients treated with nivolumab were still alive compared with 17 per cent for the comparator arm.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "This is a weak point for the release. Vaguely exciting terms, such as \u201cgame changer,\u201d have no place in a news release that is discussing the lives of human beings. \u201cGame changer\u201d is a term that has no objective definition. One person may think that the possibility of extending life by two months is a \u201cgame changer.\u201d Another person may see the term \u201cgame changer\u201d and think that it must mean they\u2019ve found a new way to put head and neck cancer into remission. This could lead to disappointment when the findings are explained in detail.\nThe release states that the drug \u201cgreatly improves survival\u201d \u2014 and perhaps within the oncology community this may be appreciated as an improvement for this type of refractory cancer. But in patient terms we are talking months of survival. All of the study participants had died by 18 months.", "answer": 0}, {"article": "That's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\nThere's also evidence that fatty acids interact with chemical signaling in the brain.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There does not appear to be a news release associated with this story.\u00a0\u00a0", "answer": 2}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nHoney also beat out no treatment at all.\nHoney has long been used by some parents as an alternative treatment for cough, although it should not be given to children under 1 year old.\n\"It's kind of amazing that something so simple could be an answer,\" Paul said.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "There is no way to know if the story relied on a press release as the sole source of information.", "answer": 2}, {"article": "\u201cOur study essentially shows that what happens in the real world is very different\u201d from what happens in clinical trials, said Hillel R. Alpert of Harvard, a co-author with Dr. Connolly and Lois Biener of the , .\n\u201cI ran a treatment program for years, and we invested\u201d millions in treatment services.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\nThe researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story did not rely on any press release.", "answer": 1}, {"article": "Oral infections, such as thrush, also may be diminished.\nThe transdisciplinary team, including William Ray, Department of Biochemistry; Andrea Dietrich, of the Charles E. Via Jr. Department of Civil and Environmental Engineering in the College of Engineering; and Glenn Lesser, from Wake Forest Baptist Medical Center, previously identified the role of lactoferrin, a specific milk protein, in diminishing the metallic flavor stimulated by chemotherapy medications.\n\"Our research shows that daily lactoferrin supplementation elicits changes in the salivary protein profiles in cancer patients - changes that may be influential in helping to protect taste buds and odor perception,\" said Duncan.\n\"By suggesting lactoferrin as a dietary supplement, we can reduce TSA for many patients, restoring their ability to enjoy foods during a time in which nutrition can play a key role in their recovery.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "A preliminary study that relies heavily upon a highly subjective questionnaire completed by just 12 patients does NOT justify a headline/subhead like this:\n\u201cMilk protein shown to alleviate chemotherapy side effects: Findings could bring relief to millions of patients undergoing cancer treatment.\u201d\n\u201cOur results suggest lactoferrin may be developed as an effective dietary supplement to treat TSA caused by chemotherapy and increase the expression of salivary proteins.\u201d\nThis statement is barely supported by the data and the extrapolation made in the news release is completely unfounded.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The story does not appear to rely on a news release, though positive anecdotal testimonials predominated the piece.", "answer": 1}, {"article": "They also conducted memory tests.\nThe men who were enrolled in Experience Corps, however, showed a .7 percent to 1.6 percent increase in brain volumes over the course of two years.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nThe brain shrinks as part of aging, but with this program we appear to have stopped that shrinkage and are reversing part of the aging process.\"\n", "question": "Does the news release include unjustifiable, sensational language, including in the quotes of researchers?", "explanation": "The suggestion that this study demonstrates \u201creversing part of the aging process,\u201d based on such a small subgroup of a small study, is an exaggeration.", "answer": 0}, {"article": "That year, Dr. Mack, who was then the president of The Society of Thoracic Surgeons, and other leaders met with the F.D.A.\n\u201cThis technology is expensive and high risk,\u201d Dr. Mack said.\n\u201cTruly phenomenal early results,\u201d Dr. Herrmann said.\nIt was written into the Medicare coverage decision, a first for a medical device.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "The article certainly goes well beyond any news release.", "answer": 1}, {"article": "On the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\nAbout 100,000 men and women age 45 and up took part in the studies.\nThe question then becomes finding out what your risk of heart attack is in the first place, which your doctor can help with.\n\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "It\u2019s clear that the story did not rely solely on a news release.", "answer": 1}, {"article": "I see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\n", "question": "Does the story appear to rely solely or largely on a news release?", "explanation": "Because there are no independent perspectives in this piece, we can\u2019t be sure of the extent to which it may have been influenced by a news release. ", "answer": 2}]